Dr. Martin Handfield Joins ONI BioPharma as Director, Research and Development

ALACHUA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. d/b/a ONI BioPharma Inc. (OTCBB:ORNI; Alternext Paris:ALONI), an American biopharmaceutical company, today announced that Dr. Martin Handfield has been appointed to the new position of Director, Research and Development. Prior to joining ONI BioPharma, Dr. Handfield was a tenured faculty member at the Center for Molecular Microbiology and Department of Oral Biology, University of Florida. Martin received his Ph.D. from Laval University in Canada and is a co-inventor of ONI BioPharma’s IVIAT platform technology that enables the rapid identification of novel and potentially important gene targets associated with the natural onset and progression of human infections. Mr. Stanley Stein, the Company’s President and Chief Executive Officer, stated, “We are delighted to have a scientist of Dr. Handfield’s stature join us. His technical and administrative experience will be of great value to the Company.”